Sartorius joins the community of the National Institute for Innovation in Manufacturing Biopharmaceuticals
Company hopes to contribute substantially to further optimizing and accelerating the current manufacturing processes in the biopharmaceutical industry.
Sartorius has joined NIIMBL, the National Institute for Innovation in Manufacturing Biopharmaceuticals headquartered in Newark, Delaware, USA.
The Institute, launched in 2017, is a public-private partnership and has an extensive network of academic and industry partners within the United States. Among the 115 associated members are 71 academic institutions, research laboratories, non-profit organizations and 44 companies – ranging from startups, small, medium and large companies. In addition, NIIMBL also engages several federal agencies. NIIMBL’s multi-pronged mission includes the following: accelerate biopharmaceutical manufacturing innovations, support the development of standards, enable more efficient and rapid manufacturing capabilities and establish an international, leading workforce to fundamentally strengthen the U.S. biopharmaceutical industry.
Recently NIIMBL expanded its membership offerings, allowing technology providers wider access to participation. Sartorius has joined the organization through this new affiliate membership program that permits the company to actively support the NIIMBL community activities. Furthermore, the program gives Sartorius the opportunity to influence the organization’s portfolio of existing innovation projects, give feedback to the review of new project proposals and directly sponsor one of the upcoming projects.
As a new member, Sartorius will initially learn about the NIIMBL technology project portfolio and seek opportunities to provide expertise on innovative ideas and solutions, including the application of existing technologies from its broad and unique product and technology portfolio. Examples such as single-use sensor technologies along with process analytical tools (PAT), data analytics and innovative solutions for next-generation bioprocessing will be among the key technologies Sartorius will contribute to these projects.
“We are very pleased that Sartorius is now a member of the NIIMBL organization and are excited about being able to collaborate with its members,” stated David J. Pollard, who heads the Advanced Materials & Processing unit at Sartorius Corporate Research. “I am convinced that with our access to the combined expertise of the NIIMBL community, we will be able to contribute substantially to further optimizing and accelerating the current manufacturing processes in the biopharmaceutical industry. As a leading partner of this industry, I see many highly interesting synergies that will result from the interface between Sartorius and NIIMBL members,” added Pollard.
”Sartorius’ extensive knowledge of biopharmaceutical process development equipment will be valuable to the community as we develop innovative manufacturing technologies,” stated Kelvin Lee, NIIMBL Institute Director.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...